FAM75C2 Inhibitors
The chemical class of FAM75C2 Inhibitors encompasses various compounds that can potentially inhibit the activity of the FAM75C2 protein, either directly or indirectly. FAM75C2 is likely involved in cellular processes regulated by signaling pathways such as the vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and epidermal growth factor receptor (EGFR) pathways, among others.
Direct inhibitors such as sorafenib, sunitinib, regorafenib, axitinib, erlotinib, ponatinib, crizotinib, vandetanib, gefitinib, afatinib, nintedanib, and lenvatinib target specific kinases or receptors involved in these pathways, potentially disrupting cellular processes that rely on FAM75C2 function. By interfering with these signaling cascades, these inhibitors can modulate the activity of FAM75C2 indirectly. These compounds serve as valuable tools for investigating the physiological roles of FAM75C2 and may have implications in diseases where dysregulation of FAM75C2-associated pathways occurs.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib is a multikinase inhibitor that targets RAF kinases, VEGFRs, and PDGFRs. By inhibiting these kinases, sorafenib disrupts signaling pathways that may intersect with those involving FAM75C2, potentially inhibiting its activity. | ||||||
Sunitinib Malate | 341031-54-7 | sc-220177 sc-220177A sc-220177B | 10 mg 100 mg 3 g | $193.00 $510.00 $1072.00 | 4 | |
Sunitinib is a multitargeted receptor tyrosine kinase inhibitor that blocks VEGFRs, PDGFRs, and other kinases. Inhibition of these receptors by sunitinib can affect downstream signaling pathways, potentially influencing FAM75C2-mediated cellular processes. | ||||||
Regorafenib | 755037-03-7 | sc-477163 sc-477163A | 25 mg 50 mg | $320.00 $430.00 | 3 | |
Regorafenib is a multikinase inhibitor targeting VEGFRs, RAF kinases, and other kinases. Its inhibitory effects on these kinases may disrupt signaling cascades involved in cellular processes regulated by FAM75C2. | ||||||
Erlotinib Hydrochloride | 183319-69-9 | sc-202154 sc-202154A | 10 mg 25 mg | $74.00 $119.00 | 33 | |
Erlotinib is a selective inhibitor of the epidermal growth factor receptor (EGFR). Inhibition of EGFR by erlotinib can disrupt downstream signaling pathways that may intersect with those involving FAM75C2, potentially inhibiting its activity. | ||||||
AP 24534 | 943319-70-8 | sc-362710 sc-362710A | 10 mg 50 mg | $172.00 $964.00 | 2 | |
Ponatinib is a potent multitargeted kinase inhibitor that inhibits BCR-ABL, VEGFRs, and other kinases. Its broad inhibitory profile may interfere with signaling pathways that regulate cellular processes involving FAM75C2. | ||||||
Vandetanib | 443913-73-3 | sc-220364 sc-220364A | 5 mg 50 mg | $167.00 $1353.00 | ||
Vandetanib is a multitargeted kinase inhibitor targeting VEGFRs, EGFR, and RET. Inhibition of these kinases by vandetanib may interfere with signaling cascades that regulate cellular processes involving FAM75C2. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib is a selective inhibitor of the epidermal growth factor receptor (EGFR). By blocking EGFR activity, gefitinib can disrupt downstream signaling pathways involved in cellular processes regulated by FAM75C2. | ||||||
Afatinib | 439081-18-2 | sc-364398 sc-364398A | 5 mg 10 mg | $112.00 $194.00 | 13 | |
Afatinib is a irreversible inhibitor of EGFR, HER2, and HER4. Its inhibitory effects on these receptors can interfere with signaling pathways that intersect with those involving FAM75C2, potentially inhibiting its activity. | ||||||
BIBF1120 | 656247-17-5 | sc-364433 sc-364433A | 5 mg 10 mg | $180.00 $315.00 | 2 | |
Nintedanib is a triple angiokinase inhibitor that targets VEGFRs, PDGFRs, and FGFRs. By inhibiting these receptors, nintedanib may disrupt signaling pathways that regulate cellular processes involving FAM75C2. | ||||||
Lenvatinib | 417716-92-8 | sc-488530 sc-488530A sc-488530B | 5 mg 25 mg 100 mg | $178.00 $648.00 $1657.00 | 3 | |
Lenvatinib is a multitargeted receptor tyrosine kinase inhibitor that targets VEGFRs, FGFRs, and PDGFRs. Inhibition of these receptors by lenvatinib can interfere with signaling pathways involved in FAM75C2-mediated cellular processes. | ||||||